Celcuity INC. (CELC) — SEC Filings

Latest SEC filings for Celcuity INC.. Recent 10-K filing on Mar 26, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Celcuity INC. on SEC EDGAR

Overview

Celcuity INC. (CELC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 26, 2026: Celcuity Inc. (CELC) is a clinical-stage biotechnology company focused on developing targeted therapies for solid tumor indications. Their lead candidate, gedatolisib, a PI3K/AKT/mTOR pathway inhibitor, is being evaluated in multiple Phase 3 clinical trials. The VIKTORIA-1 trial, for HR+/HER2- advan

Sentiment Summary

Across 39 filings, the sentiment breakdown is: 37 neutral, 2 mixed. The dominant filing sentiment for Celcuity INC. is neutral.

Filing Type Overview

Celcuity INC. (CELC) has filed 3 10-K, 18 8-K, 5 10-Q, 1 DEFA14A, 9 SC 13G/A, 2 DEF 14A, 1 SC 13G with the SEC between Feb 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (39)

Related Companies

PFE

Frequently Asked Questions

What are the latest SEC filings for Celcuity INC. (CELC)?

Celcuity INC. has 39 recent SEC filings from Feb 2024 to Mar 2026, including 18 8-K, 9 SC 13G/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of CELC filings?

Across 39 filings, the sentiment breakdown is: 37 neutral, 2 mixed. The dominant sentiment is neutral.

Where can I find Celcuity INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Celcuity INC. (CELC) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

View on Read The Filing